Celecoxib (Celebrex) in the Management of Acute Renal Colic

Inclusion Criteria: Ureteral calculus <= 10 mm in largest diameter Patient elects conservative management over immediate surgical intervention Exclusion Criteria: Solitary kidney Renal insufficiency (creatinine [CR] > 1.8) Urinary infection (fever > 101 degrees Fahrenheit, positive urine culture, many bacteria on urinalysis) Allergic-type reactions to sulfonamides Patients with known hypersensitivity to celecoxib Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or nonsteroidal anti-inflammatory agents (NSAIDs) Prior history of gastrointestinal (GI) bleed or active gastric ulcer disease Pregnancy/nursing Moderate-severe hepatic dysfunction (Child-Pugh Classification B or C) Concomitant use of drugs that inhibit P450 2C9, drugs metabolized by P450 2D6, ACE inhibitors, furosemide, warfarin (and other anticoagulants, not including low-dose aspirin), fluconazole, or lithium Women of child-bearing age unwilling to use effective contraception for the duration of the trial. Significant or unstable cardiovascular disease defined as: myocardial infarction or stroke less than 3 months prior to the study randomization planned revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass surgery [CABG]) at the time of study screening angina at rest or uncontrolled angina hospitalization or emergency department visits for cardiac-related illness less than 3 months prior to randomization uncontrolled hypertension (defined as systolic blood pressure [BP] > 140 mmHg and/or diastolic BP > 90 mmHg at the baseline visit) evidence of cardiac electrophysiologic instability including history of uncontrolled complex ventricular arrhythmia, uncontrolled atrial fibrillation or flutter, or uncontrolled supraventricular tachycardias with a ventricular response heart rate of > 100 beats per minute (BPM) at rest. (Subjects whose cardiac electrophysiologic instability is controlled with a pacemaker or implantable cardioverter defibrillator (ICD) are eligible.) symptoms, signs or treatment for congestive heart failure (CHF) or known left ventricular dysfunction with ejection fraction < 40% undergone coronary bypass surgery or any major surgery (cardiac or noncardiac) or trauma within the past 3 months